Picture of Carina Healy

Carina Healy


CMS Cameron McKenna Nabarro Olswang LLP
1 West Regent Street
G2 1AP
United Kingdom
Languages English

Carina Healy is partner in our Technology team with over 20 years experience advising on commercial and IP related transactions. She specialises in lifesciences and acts for a range of biotech, speciality pharma, medical device and medical technology companies. She also has a focus on academic institutions, having worked closely with long standing clients University of Glasgow, Dundee University, and University College London for many years.

Carina regularly advises her clients on large, complex and strategically important IP and commercial arrangements, including in and out licensing, clinical trials, strategic alliances, technology development collaborations, and manufacturing, supply and distribution agreements.  She is known for being commercial and pragmatic in finding ways to help her clients and their partners achieve outcomes which are beneficial for both parties

more less

"has tremendous capacity to manage large and complex transactions, to distil the key risks, and to identify commercially sensible, pragmatic solutions"

Chambers UK

Relevant experience

  • Roslin Biomed (the “Dolly the Sheep” company) through its lifecycle and on its acquisition by Geron Corp.
  • NuCana BioMed on the in-licensing and acquisition of ProTides technology from Morvus and on its subsequent agreements for pre-clinical and clinical development of NuCana’s proprietary oncology products, including Acelarin.
  • Evexar Medical on the manufacturing and supply arrangements for its premium, single use, self-illuminated medical devices and on the supply arrangements for human tissue scaffold products
  • Consilient Health Limited on the distribution arrangements for Rewisca®.
  • Advising on the establishment and operation of the Stratified Medicine Scotland Innovation Centre, a collaborative venture between 4 universities, 4 health boards and 2 industrial partners, including drafting the consortium agreement, and negotiating agreements with suppliers of bioinformatics equipment/ next generation sequencing technology.
  • UCL Business on an investment of $20m by now MeiraGTx into Athena Vision, a spin out company established to develop gene therapy products for ocular conditions, including negotiating and advising UCLB on a complex collaboration, development and licence agreement with Meira.
  • Advising on the complex contractual, IP and revenue sharing arrangements for BloodPharma, a large multi-party research collaboration funded by Wellcome Trust, for the use of stem cells in the manufacture of red blood cells.
  • Glasgow University on many complex IP licensing arrangements over 18 years, including the licensing of vaccines to Wyeth and licensing genetically engineered seed strains to Bayer.
  • Dundee University on the arrangements for a large phase IV clinical trial conducted through the Scottish Primary Care Network for a global pharmaceutical company.
  • Yantai Jereh, a Chinese oil and gas company, on the in-licensing of various products and technologies from Plexus Plc for development and commercialisation in various Asian markets.
more less


1995 - Law, Dip LP. University of Glasgow, Glasgow

1994 - Law, LLB (Hons), University of Glasgow, Glasgow

Dual Qualified in Scots and English Law

more less


Show only
Our ehealth capabilities
Supreme Court rules again on interpretation of contracts: busines...
In Wood v Capita Insurance Services Limited [2017] UKSC 24, the Supreme Court has sought to reconcile the approach to contractual construction and interpretation adopted by the Supreme Court in Rainy Sky v Kookmin Bank [2011] UKSC 50 and Arnold v Britton [2015].
Transformation: The Future of North Sea Oil and Ga...
Express yourself: the Court of Appeal reaffirms the position that...
In the recent case of Irish Bank Resolution Corp Ltd (In Special Liquidation) v Camden Market Holdings Corp [2017] EWCA Civ 7, the Court of Appeal once again considered the test for terms being implied into a contract.
Hospitality Matters - Autumn 2014
Current topics in the hotel industry
ICO draft guidance on consent under the GDPR published
The Information Commissioner’s Office (“ICO”) has opened for consultation its draft guidance on consent under the General Data Protection Regulation (“GDPR”). The ICO is accepting responses until 31 March 2017.
The Antidote - Spring 2014
Taking a look at "pharmerging" markets and the res...
Can pharma keep up with the challenges of digital healthcare?
Please click here to read the full article. Pharma companies are beginning now to focus on harnessing advances in digital technologies in their businesses, from mining genomic data to identify new drug targets, to establishing the most appropriate patients.
Third party rights Bill introduced in Scotland
Further to our recent Law-Now, the Contract (Third Party Rights) (Scotland) Bill (“the Bill”) is now making its way through the Scottish Parliament. The Bill, which the Scottish Government is introducing with the intention of making the law more flexible, up-to-date.
Acceptance or counter-offer?
In Caroline Gibbs v Lakeside Developments Ltd [2016] EWHC 2203, the High Court considered whether an email and attachment constituted acceptance or counter-offer. As this is an English decision, it is not technically binding in Scotland but it is highly persuasive.
Investigatory Powers Bill becomes law
The Investigatory Powers Act 2016 (the “Act”) has recently received Royal Assent and become law. Replacing the Regulation of Investigatory Powers Act 2000, the Act details the powers the police, security and intelligence agencies hold which allow them to collect.
Notice provisions – take note!
The Court of Session has recently illustrated the importance of strictly complying with notice clauses. In Hoe International Limited v Martha Andersen and Sir James Aykroyd [2016] CSOH 33, the Court confirmed that compliance with the terms of mandatory notice.
Commercial Contracts Bulletin September 2016
In this issue, we have considered significant and recent court decisions which are likely to affect the way you do business. We believe these decisions could have an impact on the way that you, your customers, your suppliers and your competitors enter into.
Third party rights in Scotland (update)
In our recent Law-Now, we explained that the Scottish Law Commission (SLC) has published a Report and draft Contract (Third Party Rights) (Scotland) Bill with proposals for reform of the Scots law of third party rights.
University ordered to disclose clinical trial data to a third par...
In Queen Mary University of London v Information Commissioner EA/2015/0269, the First-Tier Tribunal held that anonymised clinical trial data is not exempt from disclosure under The Freedom of Information Act 2000 (FOIA).
University ordered to disclose clinical trial data to a third par...
In Queen Mary University of London v Information Commissioner EA/2015/0269, the First-Tier Tribunal held that anonymised clinical trial data is not exempt from disclosure under The Freedom of Information Act 2000 (FOIA).
MHRA issues updated guidance on ehealth stand-alone software (inc...
The Medicines and Healthcare products Regulatory Agency (“MHRA”) has updated its guidance on stand-alone software including apps (the “Updated Guidance”). The Updated Guidance sets out the MHRA’s interpretation of the Medical Devices Directive (93/42/EEC) and.
EU Commission releases draft Privacy Code of Conduct for mHealth...
The European Commission has drafted a code of conduct on privacy for mobile health (mHealth) apps (the “Code”). The Code has been submitted to the Article 29 Data Protection Working Group for approval.